Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANIK
#2995
Anika Therapeutics Inc
14.360
0
+14.42%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+14.42%
Mudança mensal
+55.50%
Mudança em 6 meses
+41.62%
Mudança anual
+41.62%
Fechamento anterior
12.550
0
Open
14.360
0
Bid
Ask
Low
14.360
0
High
14.360
0
Volume
44
Mercados
Ações
Cuidados de saúde
ANIK
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
14.33 M
14.47 M
14.63 M
14.85 M
14.18 M
—
Valuation ratios
Enterprise value
552.74 M
423.97 M
345.05 M
263.63 M
177.71 M
516.83 M
Price to earnings ratio
-26.78
127.96
-28.9
-4.02
-4.3
-14.88
Price to sales ratio
4.93
3.55
2.75
1.99
2.02
6.08
Price to cash flow ratio
49.27
62.44
97.36
185.74
44.85
137.02
Price to book ratio
2.36
1.83
1.5
1.56
1.57
2.37
Enterprise value to EBITDA ratio
-9.28
-41.24
-28.67
-3.36
-29.24
-41.01
Profitability ratios
Return on assets %
0.07
0.01
0.04
0.31
0.28
0.17
Return on equity %
0.09
0.01
0.05
0.39
0.37
0.22
Return on invested capital %
50.18
1.3
28.3
200.62
-20.05
49.65
Gross margin %
52.91
56.12
59.89
61.85
63.38
218.99
Operating margin %
21.71
1.77
12.42
52.58
4.25
45.11
EBITDA margin %
-45.63
-6.96
-7.7
-47.08
-5.07
-51.21
Net margin %
18.38
2.8
9.51
49.6
47.02
112.51
Liquidity ratios
Quick ratio
3.56
4.45
4.65
3.76
3.85
17.98
Current ratio
4.81
5.66
6.07
5.26
4.88
22.1
Inventory turnover
1.8
1.58
1.65
1.48
1.25
2.39
Asset turnover
0.37
0.41
0.45
0.54
0.51
0.57
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
0.57
0.3
0.12
0.37
0.56
EBIT per share
-5.15
-1.69
-1.83
-6.32
-0.8
-1.42
EBITDA per share
-4.19
-0.7
-0.83
-5.35
-0.41
-0.99
Total debt per share
—
—
—
—
—
—
Cash per share
6.91
6.45
8.31
7.43
5.38
21.53
Net current asset value per share
12.47
11.52
11.64
11.14
7.72
28.78
Tangible book value per share
12.15
13.46
13.98
13.65
9.81
38.52
Working capital per share
9.88
9.48
9.73
9.02
6.14
23.51
Book value per share
19.15
19.62
19.61
14.48
10.46
41.19
Notícias
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Q4 2025: рост коммерческих продаж компенсирует спад OEM
Anika Q4 2025 slides: commercial surge offsets OEM decline
Anika: доходы, прибыль побили прогнозы в Q4
Anika earnings beat by $0.45, revenue topped estimates
Lumicell appoints Cheryl Blanchard to board of directors
Anika Therapeutics назначает Стивена Гриффина новым CEO
Anika Therapeutics names Stephen Griffin as new CEO
Anika в 3 кв. 2025: рост коммерческого канала компенсирует спад OEM
Anika Q3 2025 slides: Commercial growth offsets OEM decline
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika earnings beat by $0.22, revenue was in line with estimates